-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Contrasting Tarsus Pharmaceuticals (NASDAQ:TARS) & Icosavax (NASDAQ:ICVX)
Contrasting Tarsus Pharmaceuticals (NASDAQ:TARS) & Icosavax (NASDAQ:ICVX)
Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating) and Icosavax (NASDAQ:ICVX – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.
Profitability
This table compares Tarsus Pharmaceuticals and Icosavax's net margins, return on equity and return on assets.
Get Tarsus Pharmaceuticals alerts:Net Margins | Return on Equity | Return on Assets | |
Tarsus Pharmaceuticals | -324.99% | -31.56% | -28.14% |
Icosavax | -1,326.23% | -35.68% | -34.24% |
Valuation & Earnings
This table compares Tarsus Pharmaceuticals and Icosavax's gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Tarsus Pharmaceuticals | $57.03 million | 7.78 | -$13.83 million | ($2.70) | -6.16 |
Icosavax | $7.80 million | 37.79 | -$66.97 million | ($2.93) | -2.53 |
Insider and Institutional Ownership
70.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.4% of Icosavax shares are owned by institutional investors. 33.1% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 39.1% of Icosavax shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings for Tarsus Pharmaceuticals and Icosavax, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Tarsus Pharmaceuticals | 0 | 0 | 3 | 1 | 3.25 |
Icosavax | 0 | 0 | 4 | 0 | 3.00 |
Tarsus Pharmaceuticals currently has a consensus target price of $52.75, suggesting a potential upside of 217.01%. Icosavax has a consensus target price of $37.90, suggesting a potential upside of 410.78%. Given Icosavax's higher probable upside, analysts clearly believe Icosavax is more favorable than Tarsus Pharmaceuticals.
Summary
Tarsus Pharmaceuticals beats Icosavax on 8 of the 14 factors compared between the two stocks.
About Tarsus Pharmaceuticals
(Get Rating)
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
About Icosavax
(Get Rating)
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating) and Icosavax (NASDAQ:ICVX – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.
塔爾蘇斯製藥(納斯達克:TARS-GET Rating)和艾柯薩克斯(納斯達克:ICVX-GET Rating)都是小盤醫療公司,但哪隻股票更好?我們將根據這兩家公司的收益、風險、估值、機構所有權、盈利能力、分析師建議和股息的實力進行比較。
Profitability
盈利能力
This table compares Tarsus Pharmaceuticals and Icosavax's net margins, return on equity and return on assets.
此表比較了Tarsus製藥公司和ICosavax公司的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Tarsus Pharmaceuticals | -324.99% | -31.56% | -28.14% |
Icosavax | -1,326.23% | -35.68% | -34.24% |
淨利潤率 | 股本回報率 | 資產回報率 | |
塔爾蘇製藥公司 | -324.99% | -31.56% | -28.14% |
伊科薩克斯 | -1,326.23% | -35.68% | -34.24% |
Valuation & Earnings
估值與收益
This table compares Tarsus Pharmaceuticals and Icosavax's gross revenue, earnings per share (EPS) and valuation.
該表格比較了塔爾蘇斯製藥公司和ICosavax的毛收入、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Tarsus Pharmaceuticals | $57.03 million | 7.78 | -$13.83 million | ($2.70) | -6.16 |
Icosavax | $7.80 million | 37.79 | -$66.97 million | ($2.93) | -2.53 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
塔爾蘇製藥公司 | 5,703萬美元 | 7.78 | -1,383萬美元 | ($2.70) | -6.16 |
伊科薩克斯 | 780萬美元 | 37.79 | -6,697萬元 | ($2.93) | -2.53 |
Insider and Institutional Ownership
內部人與機構持股
70.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.4% of Icosavax shares are owned by institutional investors. 33.1% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 39.1% of Icosavax shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
塔爾蘇斯製藥公司70.0%的股份由機構投資者持有。相比之下,Icoavax 79.4%的股份由機構投資者持有。塔爾蘇斯製藥公司33.1%的股份由公司內部人士持有。相比之下,Icoavax 39.1%的股份由公司內部人士持有。強大的機構持股表明,大型基金管理公司、對衝基金和捐贈基金相信,一隻股票的長期表現將好於大盤。
Analyst Recommendations
分析師建議
This is a summary of current ratings for Tarsus Pharmaceuticals and Icosavax, as reported by MarketBeat.com.
這是MarketBeat.com報道的Tarsus PharmPharmticals和ICosavax的當前評級摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Tarsus Pharmaceuticals | 0 | 0 | 3 | 1 | 3.25 |
Icosavax | 0 | 0 | 4 | 0 | 3.00 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
塔爾蘇製藥公司 | 0 | 0 | 3 | 1 | 3.25 |
伊科薩克斯 | 0 | 0 | 4 | 0 | 3.00 |
Tarsus Pharmaceuticals currently has a consensus target price of $52.75, suggesting a potential upside of 217.01%. Icosavax has a consensus target price of $37.90, suggesting a potential upside of 410.78%. Given Icosavax's higher probable upside, analysts clearly believe Icosavax is more favorable than Tarsus Pharmaceuticals.
Tarsus PharmPharmticals目前的共識目標價為52.75美元,暗示潛在上行217.01%。Icoavax的普遍目標價為37.9美元,暗示潛在上漲410.78%。考慮到ICosavax更有可能的上行空間,分析師們顯然認為ICosavax比Tarsus PharmPharmticals更有利。
Summary
摘要
Tarsus Pharmaceuticals beats Icosavax on 8 of the 14 factors compared between the two stocks.
Tarsus PharmPharmticals在兩隻股票之間進行比較的14個因素中,有8個超過了Icoavax。
About Tarsus Pharmaceuticals
關於塔爾蘇製藥公司
(Get Rating)
(獲取評級)
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
塔爾蘇斯製藥公司是一家臨牀階段的生物製藥公司,專注於眼科疾病的新型候選治療藥物的開發和商業化。它的主要候選產品是TP-03,這是一種新的治療方法,處於第三階段,用於治療蠕形蟎感染引起的眼緣炎,以及治療眉毛腺疾病。該公司還在開發用於治療酒渣鼻的TP-04和用於萊姆預防和社區減少瘧疾的TP-05。此外,該公司還開發了洛替蘭,用於治療人類醫學中各種疾病,包括眼睛護理、皮膚病和其他疾病。塔爾蘇斯製藥公司成立於2016年,總部設在加利福尼亞州歐文。
About Icosavax
關於ICosavax
(Get Rating)
(獲取評級)
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
ICosavax,Inc.是一家生物製藥公司,開發針對傳染病的疫苗。該公司在其病毒樣顆粒(VLP)平臺技術的幫助下,主要專注於威脅生命的呼吸道疾病。該公司正在籌備的產品包括IVX-121,一種以RSV為靶標的候選疫苗,正處於1/1b期臨牀試驗;IVX-A12,一種具有RSV/人偏肺病毒(HMPV)二價靶標的呼吸道合胞病毒(RSV)單價抗原候選;IVX-241,一種以hMPV為靶標的疫苗候選;以及IVX-411,一種具有SARS-CoV-2靶標的原始受體結合結構域(RBD)序列抗原,正處於1/2期臨牀試驗。該公司成立於2017年,總部位於華盛頓州西雅圖。
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《塔爾蘇斯醫藥日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Tarsus製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧